HealthQuill Newborns
An advisory committee of the USFDA has given a “favourable benefit-risk profile” for Sanofi and AstraZeneca’s experimental drug nirsevimab, meant to treat lower respiratory tract disease in newborns, according to a statement from the Paris-based firm.
Drugs Health Pharma

FDA’s advisory panel backs Sanofi, AstraZeneca’s investigational drug for newborns

HQ Team June 9, 2023: An advisory committee of the USFDA has given a “favourable benefit-risk profile” for Sanofi and AstraZeneca’s experimental drug.

Read More
Seven newborns have died in France due to severe neonatal sepsis associated with enterovirus during the more than one-year period starting July 2022, the WHO stated.
Drugs Health Medical Pharma

France reports a rapid rise in severe neonatal sepsis since July 2022

HQ Team June 1, 2023: Seven newborns have died in France due to severe neonatal sepsis associated with enterovirus during the more than.

Read More
Dengue viral infection has increased from 505,430 cases in 2000 to 5.2 million in 2019, and its spread among humans is increasing globally, the WHO stated
Climate Health Pharma

Dengue viral infections on the rise globally: WHO

HQ Team April 6, 2023: Dengue viral infection has increased from 505,430 cases in 2000 to 5.2 million in 2019, and its spread.

Read More
X